Form D · Biotechnology
TenSixty Biosciences, Inc.
Cambridge, MA · CIK 0001943950
Offering snapshot reported Aug 24, 2022 · SEC filing
- Reported sold
- $7.2M Offering amount: $7.2M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 15, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 24, 2022 | Initial | $7,200,000 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-456881
Source: Form D, filed Aug 24, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sara Choi | Director |
| Karthik Jagadeesh | Director, Executive |
| Daniel Montoro | Director, Executive |
| Christoph Muus | Director |
| Dipchand Nishar | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
750 Main Street
Cambridge, MA, 02139
Cambridge, MA, 02139